Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy

Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was...

Full description

Bibliographic Details
Main Authors: Sumit Randhir Singh, Niroj Kumar Sahoo, Nallamasa Rohit Goud, Jay Chhablani
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Ophthalmology
Subjects:
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh
id doaj-e1cbb80982c747ae89c4c2f70ec01983
record_format Article
spelling doaj-e1cbb80982c747ae89c4c2f70ec019832020-11-24T21:52:49ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892019-01-016771114111810.4103/ijo.IJO_638_18Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathySumit Randhir SinghNiroj Kumar SahooNallamasa Rohit GoudJay ChhablaniPurpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile.http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=SinghIntravitreal bevacizumabintravitreal ziv-afliberceptpolypoidal choroidal vasculopathy
collection DOAJ
language English
format Article
sources DOAJ
author Sumit Randhir Singh
Niroj Kumar Sahoo
Nallamasa Rohit Goud
Jay Chhablani
spellingShingle Sumit Randhir Singh
Niroj Kumar Sahoo
Nallamasa Rohit Goud
Jay Chhablani
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
Indian Journal of Ophthalmology
Intravitreal bevacizumab
intravitreal ziv-aflibercept
polypoidal choroidal vasculopathy
author_facet Sumit Randhir Singh
Niroj Kumar Sahoo
Nallamasa Rohit Goud
Jay Chhablani
author_sort Sumit Randhir Singh
title Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
title_short Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
title_full Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
title_fullStr Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
title_full_unstemmed Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
title_sort comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Ophthalmology
issn 0301-4738
1998-3689
publishDate 2019-01-01
description Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile.
topic Intravitreal bevacizumab
intravitreal ziv-aflibercept
polypoidal choroidal vasculopathy
url http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh
work_keys_str_mv AT sumitrandhirsingh comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy
AT nirojkumarsahoo comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy
AT nallamasarohitgoud comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy
AT jaychhablani comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy
_version_ 1725874668190040064